{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T23:34:46Z","timestamp":1778283286017,"version":"3.51.4"},"reference-count":17,"publisher":"SAGE Publications","issue":"5","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Takeda Development Center Americas, Inc."}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Therapy"],"published-print":{"date-parts":[[2023,10]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Cytomegalovirus (CMV) infection is a frequent complication in haematopoietic cell\/solid organ transplant (HCT\/SOT) recipients. Previous studies report all-cause mortality rates of 31% and 50% in HCT\/SOT recipients post-treatment initiation with conventional anti-CMV therapies for refractory or resistant CMV.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This was a multi-country, retrospective medical chart review study of HCT\/SOT recipients with refractory CMV infection with or without resistance (R\/R) who were randomized to the maribavir arm in the open-label Phase 3 SOLSTICE trial. Patients came from 21 SOLSTICE sites across 6 countries; each site randomized \u22653 patients to the maribavir arm. Patients were followed for 52\u00a0weeks (SOLSTICE trial period: 20\u00a0weeks; follow-up chart review period: 32\u00a0weeks). The primary outcomes were mortality and graft status.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 234 patients who were randomized and received maribavir in SOLSTICE, chart abstraction was completed for all 109 patients enrolled across 21 trial sites (SOT, 68\/142; HCT, 41\/92). At 52\u00a0weeks, overall mortality was 15.6% (17\/109) and survival probability was 0.84. Among SOT recipients, survival probability was 0.96, and 3 (4.4%) deaths occurred during the chart review period. For the HCT recipients, survival probability was 0.65 with 14 (34.1%) deaths; 8 occurred during SOLSTICE and 6 during the chart review period. No new graft loss or re-transplantation occurred during the chart review period.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Overall mortality at 52\u00a0weeks post-maribavir treatment initiation in this sub-cohort of patients from the SOLSTICE trial was lower than that previously reported for similar populations treated with conventional therapies for R\/R cytomegalovirus infection.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/13596535231195431","type":"journal-article","created":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T18:21:11Z","timestamp":1693592471000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":9,"title":["Retrospective chart review of transplant recipients with cytomegalovirus infection who received maribavir in the Phase 3 SOLSTICE trial: Data at 52\u00a0weeks post-maribavir treatment initiation"],"prefix":"10.1177","volume":"28","author":[{"given":"Marielle","family":"Bassel","sequence":"first","affiliation":[{"name":"Evidera PPD, St-Laurent, QC, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dorothy","family":"Romanus","sequence":"additional","affiliation":[{"name":"Takeda Development Center Americas, Inc., Lexington, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tien","family":"Bo","sequence":"additional","affiliation":[{"name":"Takeda Development Center Americas, Inc., Lexington, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aimee K","family":"Sundberg","sequence":"additional","affiliation":[{"name":"Takeda Development Center Americas, Inc., Lexington, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra","family":"Okala","sequence":"additional","affiliation":[{"name":"Evidera PPD, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2293-865X","authenticated-orcid":false,"given":"Ishan","family":"Hirji","sequence":"additional","affiliation":[{"name":"Takeda Development Center Americas, Inc., Lexington, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2023,9,1]]},"reference":[{"key":"bibr1-13596535231195431","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0000000000000160"},{"key":"bibr2-13596535231195431","doi-asserted-by":"publisher","DOI":"10.4084\/MJHID.2016.031"},{"key":"bibr3-13596535231195431","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(15)00289-6"},{"key":"bibr4-13596535231195431","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofz003"},{"key":"bibr5-13596535231195431","doi-asserted-by":"publisher","DOI":"10.6061\/clinics\/2015(07)09"},{"key":"bibr6-13596535231195431","doi-asserted-by":"publisher","DOI":"10.5935\/0101-2800.20170074"},{"key":"bibr7-13596535231195431","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.25895"},{"key":"bibr8-13596535231195431","doi-asserted-by":"publisher","DOI":"10.1111\/tid.13521"},{"key":"bibr9-13596535231195431","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-0012.2007.00761.x"},{"key":"bibr10-13596535231195431","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0000000000001418"},{"key":"bibr11-13596535231195431","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cix259"},{"key":"bibr12-13596535231195431","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01787-07"},{"key":"bibr13-13596535231195431","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.77.2.905-914.2003"},{"key":"bibr14-13596535231195431","doi-asserted-by":"publisher","DOI":"10.1002\/rmv.615"},{"key":"bibr15-13596535231195431","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1000275"},{"key":"bibr16-13596535231195431","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciab988"},{"key":"bibr17-13596535231195431","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2022.04.016"}],"container-title":["Antiviral Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/13596535231195431","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/13596535231195431","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/13596535231195431","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T12:53:12Z","timestamp":1777380792000},"score":1,"resource":{"primary":{"URL":"http:\/\/journals.sagepub.com\/doi\/10.1177\/13596535231195431"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,1]]},"references-count":17,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["10.1177\/13596535231195431"],"URL":"https:\/\/doi.org\/10.1177\/13596535231195431","relation":{},"ISSN":["1359-6535","2040-2058"],"issn-type":[{"value":"1359-6535","type":"print"},{"value":"2040-2058","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,1]]},"article-number":"13596535231195431"}}